What do systematic reviews say?

ALK inhibitor vs any cytotoxic chemotherapy

ALK inhibitor leads to lower progression‐free survival: all participants compared with any cytotoxic chemotherapy (high certainty).

• Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer 2022 · Cochrane Headline outcomes only
  HR 0.45 [0.4, 0.52]
  6 studies · 1611 participants
  High